Page 66 - Haematologica-5

798
A. Khaibullina et al.
factor and the endothelium. Mayo Clin
Proc. 1991;66(6):621-627.
29. Kairaitis LK, Wang Y, Gassmann M, Tay
YC, Harris DC. HIF-1alpha expression fol- lows microvascular loss in advanced murine adriamycin nephrosis. Am J Physiol Renal Physiol. 2005;288(1):F198-206.
30. Blouin MJ, De Paepe ME, Trudel M. Altered hematopoiesis in murine sickle cell disease. Blood. 1999;94(4):1451-1459.
31. Kawaguchi M, Orikawa H, Baba T, Fukushima T, Kataoka H. Hepatocyte growth factor activator is a serum activator of single-chain precursor macrophage-stim- ulating protein. FEBS J. 2009;276(13):3481- 3490.
32. Prasain N, Stevens T. The actin cytoskele- ton in endothelial cell phenotypes. Microvasc Res. 2009;77(1):53-63.
33. Wagh PK, Peace BE, Waltz SE. Met-related receptor tyrosine kinase Ron in tumor growth and metastasis. Adv Cancer Res. 2008;100:1-33.
34. Haymann JP, Stankovic K, Levy P, et al. Glomerular hyperfiltration in adult sickle cell anemia: a frequent hemolysis associat- ed feature. Clin J Am Soc Nephrol. 2010;5(5):756-761.
35. Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE. Glomerular hyperfil- tration and albuminuria in children with sickle cell anemia. Pediatr Nephrol. 2011;26(8):1285-1290.
36. Pober JS, Cotran RS. Cytokines and endothelial cell biology. Physiol Rev.
1990;70(2):427-451.
37. Wertheimer SJ, Myers CL, Wallace RW,
Parks TP. Intercellular adhesion molecule-1 gene expression in human endothelial cells. Differential regulation by tumor necrosis factor-alpha and phorbol myristate acetate. J Biol Chem. 1992;267(17):12030-12035.
38. Cao Q, Harris DC, Wang Y. Macrophages in kidney injury, inflammation, and fibro- sis. Physiology. 2015;30(3):183-194.
39. Hill GS, Delahousse M, Nochy D, Mandet C, Bariety J. Proteinuria and tubulointersti- tial lesions in lupus nephritis. Kidney Int. 2001;60(5):1893-1903.
40. Rollino C, Basolo B, Roccatello D, Menegatti E, Piccoli G. Atypical presence of antimyeloperoxidase antibodies in 2 trans- planted patients. Nephron. 1993;63(4):480.
promote tubular regeneration after acute injury. J Am Soc Nephrol. 2008;19(10): 1904-1918.
45. Nath KA, Hebbel RP. Sickle cell disease: renal manifestations and mechanisms. Nat Rev Nephrol. 2015;11(3):161-171.
46. Zhang K, Yao HP, Wang MH. Activation of RON differentially regulates claudin expression and localization: role of claudin- 1 in RON-mediated epithelial cell motility. Carcinogenesis. 2008;29(3):552-559.
47. Sultana C, Shen Y, Rattan V, Johnson C, Kalra VK. Interaction of sickle erythrocytes with endothelial cells in the presence of endothelial cell conditioned medium induces oxidant stress leading to transendothelial migration of monocytes. Blood. 1998;92(10):3924-3935.
48. Juncos JP, Grande JP, Croatt AJ, et al. Early and prominent alterations in hemodynam- ics, signaling, and gene expression follow- ing renal ischemia in sickle cell disease. Am J Physiol Renal Physiol. 2010;298(4):F892-
41. Tomlinson ML, Garcia-Morales C, Abu-
Elmagd M, Wheeler GN. Three matrix met- alloproteinases are required in vivo for macrophage migration during embryonic development. Mech Dev. 2008;125(11- 12):1059-1070. 899.
42. Darragh MR, Bhatt AS, Craik CS. MT-SP1 proteolysis and regulation of cell-microen- vironment interactions. Front Biosci. 2008;13:528-539.
43. Rampino T, Collesi C, Gregorini M, et al. Macrophage-stimulating protein is pro- duced by tubular cells and activates mesan- gial cells. J Am Soc Nephrol. 2002;13(3): 649-657.
44. Cantaluppi V, Biancone L, Romanazzi GM, et al. Macrophage stimulating protein may
49. Brenner BM, Lawler EV, Mackenzie HS. The hyperfiltration theory: a paradigm shift in nephrology. Kidney Int. 1996;49(6):1774-1777.
50. Bieniasz M, Radhakrishnan P, Faham N, De La O JP, Welm AL. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts. Clin Cancer Res. 2015;21(24):5588-5600.
haematologica | 2018; 103(5)